Across TCGA pan-cancer cohorts, C17orf97 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C17orf97 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher C17orf97 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C17orf97 expression acts as an unfavorable survival marker.
LUSC, COAD, and LUAD are the cancer types where C17orf97 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.